A combined approach targeting ER, HER2, and RB1 yielded promising results in terms of Ki-67 expression in women with HER2-positive, ER-positive breast cancer.
HER2-Positive Breast Cancer
This video reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.
Dual HER2 blockade with lapatinib and trastuzumab plus AI therapy was more effective than trastuzumab plus AI alone in HER2+, HR+ metastatic breast cancer.
Cardiac effects of pertuzumab and trastuzumab following chemotherapy in the neoadjuvant setting were limited for HER2-positive breast cancer patients.
Disease-free survival after 9 weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to disease-free survival after 1 year of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer.
The combination of pembrolizumab and trastuzumab showed promising clinical benefit in patients with trastuzumab-resistant HER2-positive advanced breast cancer who express PD-L1, according to a new study.
Adding trastuzumab to adjuvant chemotherapy did not result in improved rates of invasive disease-free survival in patients with early-stage breast cancer and low levels of HER2 expression, according to a new study.
Traditional neoadjuvant chemotherapy along with dual HER2-targeted blockade yielded significantly better response rates than a novel approach using HER2-targeted chemotherapy plus HER2-targeted blockade, according to a randomized phase III trial.
A 5-year follow-up analysis showed that 1 year of extended adjuvant therapy with neratinib, given after chemotherapy and trastuzumab, can significantly improve rates of clinically relevant relapses in women with HER2-positive breast cancer.
Adding trastuzumab to anthracycline and taxane-based chemotherapy does not result in worsening of long-term cardiac outcomes in patients with node-positive, HER2-positive early breast cancer, according to a new study.